DAWNRAYS PHARMACEUTICAL HLDGS financial statements, including revenue, expenses, profit, and loss

The total revenue of 2348 for the last semiannual is 625.74 M HKD, and it's 15.56% higher compared to the previous semiannual. The net income of H1 24 is 534.28 M HKD.